Lilly Presents Positive Results for Taltz & #194; & #174; (ixekizumab) in Pediatric ...

Taltz is the first and only IL-17A inhibitor with published clinical trial results in pediatric patients with moderate to severe plaque psoriasis Indianapolis, Oct. 12, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that Taltz met co-primary endpoints as well as all major secondary endpoints in a Phase 3 study in pediatric patients with moderate to severe plaque psoriasis, demonstrating that 89 percent of patients treated with Taltz achieved a significant...This story is related to the following:Pharmaceuticals
Source: Industrial Newsroom - Health, Medical and Dental Supplies - Category: Medical Devices Source Type: news